Brought to you by 
Kyowa Hakko gets exclusive rights to Sandoz's rituximab biosimilar in Japan
29 Jan 2016
Executive Summary
Novartis AG's Japanese generics unit Sandoz KK granted Kyowa Hakko Kirin Co. Ltd. exclusive rights to sell a biosimilar rituximab in Japan.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Kyowa Hakko gets exclusive rights to Sandoz's rituximab biosimilar in Japan
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice